TS-064843 — , T2022-244, T2020-109 : Cancer vaccines targeting a combination
of B Cell epitopes to improve patient outcomes.
The Need
Despite the clinical success of checkpoint receptor blockade in various cancer subtypes, many patients develop resistance, presenting a pressing need for novel approaches. Current inhibitors, like PD-1/PD-L1 and HER-2 exhibit limited efficacy and significant toxicities, underscoring the d…